📣 New Value in Health call for papers! 📣
Editors seek papers on the theme Evaluating Genomic and Precision Medicine.
More info here: https://ow.ly/wpW150ZXgI2
@ispor.bsky.social
@ispor.bsky.social📣 New Value in Health call for papers! 📣
Editors seek papers on the theme Evaluating Genomic and Precision Medicine.
More info here: https://ow.ly/wpW150ZXgI2
@abangelabs.bsky.socialPoland backs Basecal 200 reimbursement for six rare metabolic disorders. https://www.mattheneus.com/editorial/aotmit-basecal-200-protein-free-formula-six-acidurias-reimbursement-consent-2026-10-12 #HTA #HealthEconomics #RegulatoryAffairs
@abangelabs.bsky.socialEvidence is not useful merely because it is technically correct. Health economics teams need a decision-use test for every output. https://www.mattheneus.com/editorial/ispor-heor-evidence-usability-decision-use-test-2026-10-15 #HTA #HealthEconomics #EvidenceSynthesis
@citizenptnewsne.bsky.socialUNMC's transplant program has not only saved over 10,000 lives but also generated an astounding $500 million for Nebraska's economy!
Learn more here
#NE #CommunityImpact #CitizenPortal #LivingDonation #HealthEconomics
@ihea.bsky.social🌍 September was an incredible month of community learning!
Our Special Interest Groups (SIGs) hosted 8 webinars, bringing together 780+ attendees.
📺 Missed a webinar? Watch the recordings: www.youtube.com/@healthecono...
@abangelabs.bsky.socialA digital diabetes value case can look compelling in year one—but cost-effectiveness depends on what happens when effects wane. https://www.mattheneus.com/editorial/digital-diabetes-matched-cohort-effect-waning-cost-effectiveness-2026-10-14 #HTA #RWE #HealthEconomics
@abangelabs.bsky.socialIron deficiency may shift HbA1c enough to distort evidence thresholds. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/biochemia-medica-iron-deficiency-hba1c-false-elevation-meta-analysis-2026-10-15
@abangelabs.bsky.socialHPV vaccine cost-effectiveness evidence doesn’t travel unchanged.
https://www.mattheneus.com/editorial/hpv-vaccination-economic-evaluation-transferability-price-threshold-screening-context-2026-10-14
#HTA #HealthEconomics #EvidenceSynthesis
@abangelabs.bsky.socialSoftware reversals aren’t always real preference inconsistency. A Nigerian child health valuation study shows why. https://www.mattheneus.com/editorial/nigeria-child-health-state-valuation-software-reversal-preference-inconsistency-2026-10-13 #HTA #HealthEconomics
@ihea.bsky.social🤝 Upcoming Networking & Mentoring Event
📅 October 21, 2026
🕛 12:00 – 1:00 PM UTC + 0
🔗 Register for the session: www.healtheconomics.org/event/networ...
Submit your abstract here: docs.google.com/spreadsheets...
#Networking #Mentoring #HealthEconomics #HealthPolicy #HealthResearch
@abangelabs.bsky.socialHighest mean net benefit doesn’t always mean most often optimal. Why the distinction matters in HTA decisions.
https://www.mattheneus.com/editorial/rims1-gastric-surveillance-mean-net-benefit-probability-optimal-2026-10-11
#HTA #HealthEconomics
@abangelabs.bsky.socialDutch payer calls for a 63% zanubrutinib price cut in marginal zone lymphoma—an HTA signal shaped by comparative evidence. https://www.mattheneus.com/editorial/zin-zanubrutinib-brukinsa-marginal-zone-lymphoma-price-cut-maic-2026-09-22 #HTA #MAIC #HealthEconomics #Pharma
@abangelabs.bsky.socialHospital screening can look cost-saving—until one fragile effectiveness assumption moves. #HTA #HealthEconomics #EvidenceSynthesis https://www.mattheneus.com/editorial/carbapenemase-screening-effectiveness-cost-saving-transferability-2026-10-13
@nfbot.bsky.socialPoland backs coordinated rare-disease care despite rejecting a stand-alone neurofibromatosis benefit. #HTA #HealthEconomics https://www.mattheneus.com/editorial/aotmit-neurofibromatosis-coordinated-care-separate-benefit-rejection-rare-disease-centres-2026-10-0
@abangelabs.bsky.socialA mortality signal is not yet an implementation case: what payers still need from convective dialysis evidence. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/cochrane-convective-dialysis-mortality-signal-implementation-evidence-2026-10-13
@ssrn.bsky.socialThis paper finds that post-Dobbs #abortionbans are associated with a higher likelihood that women pay out-of-pocket health insurance premiums, with particularly strong effects among Black and Hispanic women. spkl.io/633207niBy
#HealthEconomics
@abangelabs.bsky.socialPoland backs coordinated rare-disease care despite rejecting a stand-alone neurofibromatosis benefit. #HTA #HealthEconomics https://www.mattheneus.com/editorial/aotmit-neurofibromatosis-coordinated-care-separate-benefit-rejection-rare-disease-centres-2026-10-07
@euroqol.bsky.socialOut now: our September publication selection 📚
8 new papers covering EQ-HWB-9 in cancer, EQ-5D Bolt-on Toolbox developments, EQ-5D-Y psychometrics in Ethiopia and Arabic-speaking populations, VAS versions, and more.
Dive in 👉 https://bit.ly/4y6Gkh2
@healtheconall.bsky.socialRSS Webinar: Good Practices on the Evaluation of Surrogate Endpoints for HTA Decision Making (24 November) #healtheconomics
@abangelabs.bsky.socialIn type 3 von Willebrand disease, bleeding-rate assumptions can decide whether prophylaxis looks cost-saving. https://www.mattheneus.com/editorial/type-3-von-willebrand-prophylaxis-cost-saving-bleeding-rate-assumptions-2026-10-13 #HTA #HealthEconomics #EvidenceSynthesis